Subscribe To
PFE / Pfizer quarterly results hit by soft demand for COVID-19 products
![Pfizer quarterly results hit by soft demand for COVID-19 products](https://cdn.snapi.dev/images/v1/z/h/pfizer-covid-vaccine-2131973.jpg)
PFE News
![Seeking High Dividends? 3 Fairly Valued/Undervalued High Dividend Yield Stocks For Your Portfolio Seeking High Dividends? 3 Fairly Valued/Undervalued High Dividend Yield Stocks For Your Portfolio](https://cdn.snapi.dev/images/v1/o/b/image-1449467037-2140586.jpg)
By Seeking Alpha
November 4, 2023
Seeking High Dividends? 3 Fairly Valued/Undervalued High Dividend Yield Stocks For Your Portfolio
High dividend yield companies are valuable assets for your portfolio, since they are a great way to generate added income, which you can reinvest or u more_horizontal
![Should You Pick Pfizer Stock At $30? Should You Pick Pfizer Stock At $30?](https://cdn.snapi.dev/images/v1/w/w/should-you-pick-pfizer-stock-at-30-2138939.jpg)
By Forbes
November 3, 2023
Should You Pick Pfizer Stock At $30?
Pfizer (NYSE: PFE) reported its Q3 results earlier this week, with revenues missing but earnings beating the street estimates, and we believe that PFE more_horizontal
![There's a Silver Lining in Pfizer's Dark Cloud. Should You Buy the Stock? There's a Silver Lining in Pfizer's Dark Cloud. Should You Buy the Stock?](https://cdn.snapi.dev/images/v1/a/b/106791886-1605096960804-gettyimages-1229031575-2138472.jpg)
By The Motley Fool
November 3, 2023
There's a Silver Lining in Pfizer's Dark Cloud. Should You Buy the Stock?
Pfizer reported an adjusted loss of nearly $1 billion in the third quarter, and recently lowered its forecasts for coronavirus product sales. The comp more_horizontal
![This High-Yield Dividend Stock Is a Proven Wealth Creator This High-Yield Dividend Stock Is a Proven Wealth Creator](https://cdn.snapi.dev/images/v1/e/q/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f7533062fgrowth-stockjpgopresizew400h400-2136419.jpg)
By The Motley Fool
November 2, 2023
This High-Yield Dividend Stock Is a Proven Wealth Creator
In 2023, the broader market has ignored the deep value proposition of most large-cap pharmaceutical stocks. Pfizer, a stalwart of the industry, has be more_horizontal
![UK regulator approves Pfizer's hair loss drug UK regulator approves Pfizer's hair loss drug](https://cdn.snapi.dev/images/v1/1/z/vjnmhrvyqrp45dlbmbacwxxdou-2132578.jpg)
By Reuters
November 1, 2023
UK regulator approves Pfizer's hair loss drug
Britain's medicines regulator on Wednesday approved Pfizer Inc's drug to treat hair loss caused by an autoimmune disease. more_horizontal
![Pfizer Posted a Steep Loss. Is It Time to Sell? Pfizer Posted a Steep Loss. Is It Time to Sell?](https://cdn.snapi.dev/images/v1/j/e/3500jpgwidth460quality85autoformatfitmaxs562e35b06414ab497c157f16bf2eac08-2132257.jpg)
By The Motley Fool
November 1, 2023
Pfizer Posted a Steep Loss. Is It Time to Sell?
Pfizer reported third-quarter results on Tuesday, Oct. 31. The company told investors it had to write down $5.6 billion worth of unused inventory in t more_horizontal
![Pfizer quarterly results hit by soft demand for COVID-19 products Pfizer quarterly results hit by soft demand for COVID-19 products](https://cdn.snapi.dev/images/v1/z/h/pfizer-covid-vaccine-2131973.jpg)
By Fox Business
October 31, 2023
Pfizer quarterly results hit by soft demand for COVID-19 products
Sales of the company's coronavirus vaccine Comirnaty dropped 70% during the third quarter compared with the same period a year earlier, Pfizer reporte more_horizontal
![We are keen to join forces with Seagan, says Pfizer CEO Albert Bourla We are keen to join forces with Seagan, says Pfizer CEO Albert Bourla](https://cdn.snapi.dev/images/v1/d/l/we-are-keen-to-join-forces-with-seagan-says-pfizer-ceo-albert-bourla-2131959.jpg)
By CNBC Television
October 31, 2023
We are keen to join forces with Seagan, says Pfizer CEO Albert Bourla
Pfizer Chairman and CEO Albert Bourla joins 'Mad Money' host Jim Cramer to talk Q3 earnings results, partnering with Kansas City Chiefs Tight End Trav more_horizontal